The Cost of Attention

How Ibogaine Became a Movement Before It Became a Science

There is a difference between building awareness and building understanding, and the recent trajectory of ibogaine is the story of what happens when the first outruns the second.

For years, ibogaine lived at the edges of medicine. Most people had never heard of it. The few who had were the Bwiti themselves, or the practitioners, clinicians, researchers, and addiction specialists who circled the compound, along with the people desperate enough to look past the conventional treatment system and willing to travel to a clinic or a tribe to do it. The substance occupied a strange and contradictory place: obscure, controversial, hard to reach, and yet quietly producing outcomes that demanded investigation. What it did not have was attention.

Then the attention arrived.

The modern psychedelic renaissance brought cameras, podcasts, conferences, documentaries, venture capital, ballot measures, and a steady stream of personal testimony. One by one, people walked out of powerful experiences convinced they had found the answer to suffering itself. Many of them meant well, and some almost certainly saved lives. But somewhere along the way the conversation began to move faster than the evidence beneath it.

Here the field made an error that deserves precision, because it can be misread in two directions at once. The first error was overreach: ibogaine became a substance that could supposedly treat everything. Addiction. PTSD. Depression. Traumatic brain injury. Anxiety. Moral injury. Chronic despair. Spiritual disconnection. The list lengthened with every interview, every stage, every headline, growing in roughly the manner of any claim repeated more often than it is tested.

The opposite error, less discussed but equally distorting, is to shrink ibogaine down to a single indication and call that humility. It is not. Ibogaine is genuinely unusual in its pharmacological breadth. It acts, along with its long-lived metabolite noribogaine, across an unusually wide set of targets, and that breadth is precisely why the compound is so interesting to study and so difficult to reduce to one mechanism. The honest position is therefore narrower than the enthusiasts and wider than the skeptics: the experience is broad, but the evidence for any given application is not uniform across that breadth.

Where the human data is strongest, it is strongest by a wide margin. The most compelling clinical promise remains opioid use disorder and severe substance dependence, where the existing human data, though limited, is genuinely striking, and where conventional treatment fails so often that the bar for “worth investigating” is easily cleared. What distinguishes ibogaine in that setting is not a vague mood benefit but two specific and unusual signals: a marked attenuation of opioid withdrawal and craving, and a set of motor and neurological effects that have drawn separate scientific interest in their own right. Past these, the ground gets softer: intriguing signals, early data, plausible hypotheses, open questions. Enough to justify serious science. Not nearly enough to support the claims that have entered public conversation.

It is also worth saying plainly what the enthusiasm tends to skip, because the omission is itself part of the pattern. The intensity of the ibogaine experience is not a feature to be celebrated. It is a cost to be managed. The compound carries real cardiac risk, has measurable hepatic and neurological burden, and has killed people who took it without screening. Whether a less punishing experience, a lower dose, a different route, or a structural analog could deliver the same anti-addiction and neurological benefits with less physiological danger is one of the most important open questions in the field. It is a hypothesis worth pursuing, not a result already in hand, and the difference between those two things is the whole subject of this essay.

Science accumulates. It moves at the speed of replication, of failed studies repeated until something holds. Enthusiasm has no such governor, and when the two fall out of step the gap between them does not stay empty. It fills with belief.

This is not an argument that advocacy should never have happened. It is an argument that the advocacy should have been disciplined. It should have moved first through the people equipped to carry it: researchers, clinicians, the traditional stakeholders who have held this knowledge for generations, conservation experts, and regulators. It should have happened in working groups and study protocols before it happened on stages.

Instead, much of the public conversation was carried by people who had recently undergone the experience, were still standing inside its emotional afterglow, and happened to possess the money, charisma, or media access to amplify their own testimony. Personal transformation is real, and many of these stories gave hope to people who badly needed it. But a profound experience does not, by itself, qualify anyone to shape policy, describe mechanisms, speak for indigenous traditions, forecast public-health outcomes, or decide how a scarce botanical resource should enter modern medicine. That was the error the field kept making. It treated the intensity of an experience as if it conferred authority over the experience’s meaning.

An entire ecosystem grew up around that mistake. Conferences, foundations, fundraisers, gala dinners, and organizations all assembled themselves around the promise of accelerating progress, and many of them were sincere about it. Some did real work. But attention had become its own kind of currency, and currency draws the people who know how to accumulate it. The incentives inverted without notice. It is easier to raise awareness than to produce evidence, easier to host an event than to fund a study that might take years to read out, easier to assemble a compelling narrative than the data it claims to rest on. A field that needed scientists kept producing advocates instead, and advocacy, unlike understanding, can be manufactured on a deadline.

As enthusiasm climbed, the nations and communities that have stewarded iboga for generations watched the rest of the world discover something that had always been theirs. From their vantage point the pattern was familiar and old. Foreign governments, pharmaceutical firms, investors, advocacy groups, and media personalities were suddenly talking about a plant that grows in their forests and holds a sacred place in their tradition. Much of the world’s supply had already been leaving the country illegally, harvested from the wild and smuggled abroad to feed clinics that paid little, or nothing, back to its source.

The response was predictable, and it was reasonable. Control tightened. Export oversight increased. Conservation concern grew louder, and not without cause, since the plant grows slowly, mostly in the wild, and harvesting the root can kill it. National sovereignty over the resource became a stated priority. What many advocates read as progress looked, from the forests of Gabon, like the early stages of extraction. That perception matters whether or not it is accurate in every particular, because perception is what shapes policy.

Today Gabon increasingly treats iboga as a strategic national asset rather than a freely traded commodity. Its government is working to bring the plant to international markets legally, through frameworks such as the Nagoya Protocol on access and benefit-sharing, while keeping tight control over who may export and on what terms. Cultivation is being encouraged but is not yet at scale. The supply chain is narrowing at precisely the moment global demand is widening. None of this should have surprised anyone. When demand rises faster than governance, governance eventually catches up, and it rarely catches up gently.

The simplest version of this story is also the least true. It is tempting to lay the bottleneck entirely at the feet of loud advocacy, and that would be both unfair and analytically lazy. The constriction has many parents. Conservation concern is legitimate: iboga is slow-growing and the wild population is finite. Indigenous sovereignty is legitimate: the Bwiti claim to this plant and its associated knowledge predates every clinic and every patent, and Gabonese traditional knowledge currently sits outside the intellectual-property protections that would let its holders benefit from what others build on it. Commercial demand from the wellness industry and pharmaceutical interest in patentable analogs have both raised the stakes and the price. And underneath all of it lies decades of underinvestment in cultivation, so that when interest finally arrived there was no agricultural base ready to meet it. Advocacy accelerated a collision. It did not build the wall.

That fuller account sharpens the criticism. The point was never that any single group acted in bad faith. It is that awareness expanded without the surrounding infrastructure that would have let it expand safely: the supply, the studies, the legal channels, the benefit-sharing arrangements, the patient follow-up. Awareness is cheap to manufacture. Everything that makes awareness useful is slow and expensive, and the slow expensive things were the ones nobody competed to fund.

A quieter path existed, and it is worth describing because its absence is the real subject of this essay. Ibogaine could have entered the scientific process through a narrower gate. Small clinical studies. Replication. Mechanistic work. Safety infrastructure built around a compound that carries real cardiac risk and has killed people who took it without screening. Longitudinal follow-up. Human data gathered systematically across years rather than narratives gathered rapidly across months. In that version the public narrative trails the science and is corrected by it. In the version we got, the science was conscripted to chase the narrative, and it is still running to catch up.

The unfortunate truth is that ibogaine never needed to become a cultural phenomenon to matter. Its breadth is real, but breadth is not the same as proven application, and the field’s task was always to map the difference rather than to erase it. Where a compound like psilocybin may eventually find use across a wide range of psychiatric conditions, ibogaine looks more like a specialist’s instrument: pharmacologically broad, clinically concentrated, its best-supported value sitting in the most severe forms of addiction, particularly opioid dependence, where standard approaches frequently fail and mortality remains staggering, alongside the distinct neurological signals that warrant study on their own terms. That alone would have been extraordinary. A medicine does not need to cure everything in order to be remarkable, and the pressure to make it cure everything is usually a sign that something other than evidence is driving the conversation.

Once a substance becomes a symbol, people begin projecting their hopes onto it. A success story turns into proof of universal potential. A private revelation becomes evidence of broad applicability. Each good outcome becomes another reason to widen the claim, until the conversation floats free of the data that was supposed to anchor it.

So we arrive somewhere peculiar. Interest, public awareness, and political attention have never been higher, and yet access to the source material is tightening, supply chains are narrowing, costs are climbing, and serious research still runs into logistical and regulatory walls. The bottleneck arrived exactly when the field began demanding scale.

I am not arguing that ibogaine should have stayed hidden. Lives have been changed because people learned it existed, and that is not nothing. I am arguing that awareness without proportional scientific development carries a cost, and that the cost is now coming due. A medicine does not become better understood because more people are talking about it. It becomes better understood because more people are studying it.

For most of its history, ibogaine’s central problem was obscurity. Now it is the distance between what is known and what is believed, and that distance has become expensive.